Free Trial

Turnstone Biologics Q2 2023 Earnings Report

Turnstone Biologics logo
$0.45 -0.05 (-10.36%)
(As of 05:27 PM ET)

Turnstone Biologics EPS Results

Actual EPS
-$7.56
Consensus EPS
-$3.01
Beat/Miss
Missed by -$4.55
One Year Ago EPS
N/A

Turnstone Biologics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Turnstone Biologics Announcement Details

Quarter
Q2 2023
Time
After Market Closes

Conference Call Resources

An extra $2 trillion a year for this industry? (Ad)

We're on the cusp of an energy revolution... I'm not talking about lithium batteries, renewable energies, or nuclear energy. This 'silent energy boom' is bigger than anything we've seen before.

Click here for the shocking truth

Turnstone Biologics Earnings Headlines

BofA downgrades Turnstone to Underperform on unfavorable market
Turnstone Biologics downgraded to Underperform from Neutral at BofA
An extra $2 trillion a year for this industry?
We're on the cusp of an energy revolution... I'm not talking about lithium batteries, renewable energies, or nuclear energy. This 'silent energy boom' is bigger than anything we've seen before.
Turnstone Biologics Faces Financial and Operational Challenges
See More Turnstone Biologics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Turnstone Biologics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Turnstone Biologics and other key companies, straight to your email.

About Turnstone Biologics

Turnstone Biologics (NASDAQ:TSBX), a clinical stage biotechnology company, focuses on developing medicines to treat and cure patients with solid tumors. The company's lead product includes TIDAL-01 that is in Phase 1 clinical trials for the treatment of breast cancer, colorectal cancer, head and neck cancer and uveal melanoma, as well as an investigator sponsored trials to treat colorectal cancer, head and neck cancer, and cutaneous and non-cutaneous melanomas. It is also developing TIDAL-02, which is in preclinical development for the treatment of solid tumors. The company was founded in 2014 and is based in LA Jolla, California.

View Turnstone Biologics Profile

More Earnings Resources from MarketBeat

Upcoming Earnings